Payden & Rygel Merck & Co., Inc. Transaction History

Payden & Rygel

$1.21 Billion
Q3 2025

A detailed history of Payden & Rygel transactions in Merck & Co., Inc. stock. As of the latest transaction made, Payden & Rygel holds 197,910 shares of MRK stock, worth $18.4 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares

197,910

Previous 3,710 5234.5%

Holding current value

$18.4 Million

Previous $294,000 5550.0%

% of portfolio

1.38%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$77.6 - $87.37 $15.1 Million - $17 Million	194,200 Added 5234.5%	197,910 $16.6 Million
Q2 2025 Aug 07, 2025	SELL	$73.47 - $87.12 $271,839 - $322,344	-3,700 Reduced 49.93%	3,710 $294,000
Q1 2025 May 15, 2025	SELL	$83.01 - $101.02 $8.64 Million - $10.5 Million	-104,140 Reduced 93.36%	7,410 $665,000
Q4 2024 Feb 12, 2025	SELL	$96.31 - $114.76 $7.09 Million - $8.45 Million	-73,600 Reduced 39.75%	111,550 $11.1 Million
Q3 2024 Nov 08, 2024	BUY	$111.15 - $128.97 $7.22 Million - $8.38 Million	65,000 Added 54.1%	185,150 $21 Million

Q2 2024 Oct 07, 2024	SELL	$123.8 - $132.96 $5.78 Million - $6.21 Million	-46,700 Reduced 27.99%	120,150 $14.9 Million
Q1 2024 Oct 08, 2024	BUY	$113.24 - $131.95 $1.31 Million - $1.53 Million	11,600 Added 9.65%	131,750 $17.4 Million
Q4 2023 Feb 12, 2024	SELL	$100.18 - $109.02 $2.92 Million - $3.17 Million	-29,100 Reduced 14.85%	166,850 $18.2 Million
Q2 2023 Aug 10, 2023	SELL	$108.61 - $118.38 $4.76 Million - $5.19 Million	-43,850 Reduced 18.29%	195,950 $22.6 Million
Q1 2023 May 10, 2023	SELL	$102.94 - $114.86 $10.1 Million - $11.3 Million	-98,210 Reduced 29.06%	239,800 $25.5 Million
Q4 2022 Feb 13, 2023	SELL	$87.44 - $112.11 $5.79 Million - $7.42 Million	-66,200 Reduced 16.38%	338,010 $37.5 Million
Q3 2022 Nov 10, 2022	BUY	$84.53 - $94.96 $18.3 Million - $20.6 Million	216,800 Added 115.68%	404,210 $34.8 Million
Q2 2022 Aug 12, 2022	BUY	$83.49 - $94.64 $15.4 Million - $17.4 Million	184,000 Added 5395.89%	187,410 $17.1 Million
Q4 2021 Feb 11, 2022	SELL	$72.28 - $90.54 $34.5 Million - $43.2 Million	-477,100 Reduced 99.29%	3,410 $261,000
Q3 2021 Nov 15, 2021	BUY	$71.68 - $78.83 $4.22 Million - $4.64 Million	58,900 Added 13.97%	480,510 $36.1 Million
Q2 2021 Aug 06, 2021	SELL	$70.31 - $77.77 $154,682 - $171,094	-2,200 Reduced 0.52%	421,610 $32.8 Million
Q1 2021 May 13, 2021	BUY	$68.86 - $81.11 $8.75 Million - $10.3 Million	127,100 Added 42.84%	423,810 $32.7 Million
Q4 2020 Feb 08, 2021	SELL	$71.77 - $79.65 $10.2 Million - $11.3 Million	-142,100 Reduced 32.38%	296,710 $24.3 Million
Q3 2020 Nov 10, 2020	BUY	$73.18 - $82.95 $1.42 Million - $1.61 Million	19,400 Added 4.63%	438,810 $36.4 Million
Q2 2020 Aug 12, 2020	SELL	$70.42 - $80.13 $10.2 Million - $11.6 Million	-145,090 Reduced 25.7%	419,410 $32.4 Million
Q1 2020 May 04, 2020	BUY	$63.36 - $87.82 $3.16 Million - $4.38 Million	49,920 Added 9.7%	564,500 $43.4 Million
Q4 2019 Jan 31, 2020	SELL	$77.58 - $87.54 $178,434 - $201,342	-2,300 Reduced 0.44%	514,580 $46.8 Million
Q3 2019 Oct 30, 2019	BUY	$76.08 - $82.93 $1.17 Million - $1.28 Million	15,380 Added 3.07%	516,880 $43.5 Million
Q2 2019 Aug 06, 2019	BUY	$69.84 - $81.59 $1.02 Million - $1.19 Million	14,600 Added 3.0%	501,500 $42.1 Million
Q4 2018 Jan 25, 2019	BUY	$65.24 - $75.71 $711,116 - $825,238	10,900 Added 2.29%	486,900 $37.2 Million
Q3 2018 Nov 07, 2018	SELL	$57.69 - $67.84 $2.11 Million - $2.48 Million	-36,500 Reduced 7.12%	476,000 $33.8 Million
Q1 2018 May 09, 2018	BUY	$50.96 - $59.23 $8.19 Million - $9.52 Million	160,800 Added 45.72%	512,500 $27.9 Million
Q3 2017 Nov 14, 2017	BUY	$58.67 - $63.13 $20.6 Million - $22.2 Million	351,700	351,700 $22.5 Million

Others Institutions Holding MRK

# of Institutions

3,878

Shares Held

1.9B

Call Options Held

30.1M

Put Options Held

27.7M

View Full List

About Merck & Co., Inc.

Ticker MRK
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,533,280,000
Market Cap $235B
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...

More about MRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account